^
Association details:
| Biomarker: | EGFR exon 19 deletion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | ERAS-801 (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The CNS-penetrant EGFR inhibitor, ERAS-801, shows promising nonclinical activity in a CNS metastases model of EGFR mutant NSCLC
Published date:
10/26/2022
Excerpt:
Secreted gaussia luciferase expressing PC9 cells, which were derived from EGFR exon 19 deletion NSCLC, were intracranially injected into female NSG mice and were randomized into the following treatment groups: vehicle, osimertinib at 10 and 25 mg/kg (mpk) and ERAS-801 at 10 and 25 mpk (n = 8 mice per group)....ERAS-801 at 10 and 25 mpk achieved significantly greater tumor regressions than osimertinib in an intracranial EGFR mutant NSCLC PC9 CDX study.
DOI:
ttps://doi.org/10.1016/S0959-8049(22)00885-1
